IPCA Labs board approves merger of Krebs Biochemicals

Listed Co AcquisitionStrategic Transactions View source PDF

IPCALAB · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

+5.4%1-day move

₹1619.90

prior close

₹1618.30

base price

After-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

+1.1+0.8+1.2+2.1+5.4+4.8+6.3+9.6+9.9+8.9+13.0———

Up moveDown movePending

AI summary

IPCA Labs board approved merger of Krebs Biochemicals with itself under Sections 230-232 of the Companies Act. Appointed date April 1, 2026. Subject to NCLT and SEBI approvals. Share swap ratio: 7 IPCA shares of Re 1 each for every 200 Krebs shares of Rs 10 each. No cash consideration. Gives IPCA fermentation based API capability. Krebs FY26 income Rs 26 Cr versus IPCA Rs 7,431 Cr. Related party deal at arms length. Promoter holding dips marginally from 44.72 percent to 44.66 percent.

Likely market impact

Strengthens IPCA's API supply chain and adds fermentation capability. Minor promoter dilution. Positive for long term.